Blog
Featured post
Truveta Data leads a new era in cancer research
With more than 7 million oncology patient journeys spanning more than 100 cancer types, Truveta delivers an unprecedented breadth of regulatory grade data to support researchers in accelerating oncology therapy adoption and advancing critical cancer research.
Truveta experts: Biomarker testing trends in metastatic non-small cell lung cancer (NSCLC)
Biomarker testing has transformed cancer care over the past decade, opening the door to targeted therapies that can improve outcomes for patients with advanced disease. Yet...
Multiple sclerosis: Real-world treatment patterns and outcomes
Multiple sclerosis (MS) affects approximately 1 million people in the United States, with women representing nearly 75% of patients. Over the past decade, consensus guidelines...
ISPE 2025: Real-world data survival patterns in glioblastoma patients
Authors: Mantas Dmukauskas, PhD ⊕Truveta, Inc, Bellevue, WA, Sarah Blach, MS ⊕Truveta, Inc, Bellevue, WA, Sunny Guin, PhD ⊕Truveta, Inc, Bellevue, WA, Amy Wu ⊕Truveta, Inc,...
ISPE 2025: Active surveillance of mosquito-borne diseases in the United States
Authors: Katie Kendrick, MPH ⊕Truveta, Inc, Bellevue, WA, Amy Sullivan, MS ⊕Truveta, Inc, Bellevue, WA, Sunny Guin, PhD ⊕Truveta, Inc, Bellevue, WA, Agnes Pastwa ⊕Truveta, Inc,...
ISPE 2025: Active surveillance of foodborne diseases in the United States
Authors: Katie Kendrick, MPH ⊕Truveta, Inc, Bellevue, WA, Amy Sullivan, MS ⊕Truveta, Inc, Bellevue, WA, Sunny Guin, PhD ⊕Truveta, Inc, Bellevue, WA, Agnes Pastwa ⊕Truveta, Inc,...
ISPE 2025: A real-world risk stratification approach to pulmonary embolism using Truveta Data
Authors: Amy Austin, MS ⊕Truveta, Inc, Bellevue, WA, Emily Webber, PhD ⊕Truveta, Inc, Bellevue, WA, Sarah Blach, MS ⊕Truveta, Inc, Bellevue, WA, Jared Kern ⊕Truveta, Inc,...
How AI and real-world data are rewriting the rare disease playbook
After years of uncertainty, a recent policy change is sparking new optimism in rare disease drug development. A change in federal policy now keeps certain multi-indication rare...
Truveta experts: Sudden cardiac arrest and arrhythmias among patients with chronic kidney disease
In this edition of Truveta experts, Esther Kim, PhD, MPH, Senior Director of Research Services at Truveta, shares findings from her recent exploration of the burden of sudden...
Unlocking treatment insights through real-world discontinuation data
Why do patients stop taking a medication? Was it due to side effects, access barriers, or lack of efficacy? These are not just clinical questions; they’re strategic ones....